基于疾病状态与毒性死亡时间定期连续监测的贝叶斯I-II期设计
针对具有四个共同主要结局的临床试验,提出一种贝叶斯I-II期剂量寻找设计,连续监测疾病进展、毒性和死亡时间,并定期评估有序疾病状态。模拟研究显示,与基于常用疗效和毒性结局的简化设计相比,该设计正确选择真正最优剂量和排除真正不安全剂量的概率显著更高。
要点
- 连续监测疾病进展、毒性和死亡时间,定期影像评估有序疾病状态。
- 采用比例 hazards 模型和纵向多项 probit 模型,并引入多元脆弱性关联结局。
- 基于后验均值效用优化剂量,并设安全规则排除PD、严重毒性或死亡率过高的剂量。
核心结论
- 所提出的贝叶斯I-II期设计在模拟研究中优于基于常用疗效和毒性结局的简化设计。
研究设计与样本
- 贝叶斯I-II期剂量寻找设计,针对四个共同主要结局,在预设固定随访期内连续监测疾病进展、毒性和死亡时间,并定期影像评估有序疾病状态。
- 采用分段常数基线风险的比例风险模型和纵向多项probit模型,并引入多元患者脆弱性。
- 构建随访期内非致命结局组合的有限划分,并引出每个划分集合的效用。
主要发现
- 模拟研究显示,简化设计正确选择真正最优剂量和排除真正不安全剂量的概率显著更低。
关键数值与推荐
- 使用后验均值效用优化每个患者的剂量。
- 安全规则排除具有不可接受高的PD、严重毒性或死亡率的剂量。
临床怎么用
- 可用于同时考虑疾病进展、毒性、死亡和有序疾病状态的I-II期临床试验剂量优化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A Bayesian phase I-II dose-finding design is presented for a clinical trial with four coprimary outcomes that reflect the actual clinical observation process. During a prespecified fixed follow-up period, the times to disease progression, toxicity, and death are monitored continuously, and an ordinal disease status variable, including progressive disease (PD) as one level, is evaluated repeatedly by scheduled imaging. We assume a proportional hazards model with piecewise constant baseline hazard for each continuous variable and a longitudinal multinomial probit model for the ordinal disease status process and include multivariate patient frailties to induce association among the outcomes. A finite partition of the nonfatal outcome combinations during the follow-up period is constructed, and the utility of each set in the partition is elicited. Posterior mean utility is used to optimize each patient's dose, subject to a safety rule excluding doses with an unacceptably high rate of PD, severe toxicity, or death. A simulation study shows that, compared with the proposed design, a simpler design based on commonly used efficacy and toxicity outcomes obtained by combining the four variables described above performs poorly and has substantially smaller probabilities of correctly choosing truly optimal doses and excluding truly unsafe doses.
引用
- Lee J, F Thall P, Msaouel P, et al. A phase I-II design based on periodic and continuous monitoring of disease status and the times to toxicity and death. Stat Med. 2020. PMID: 32255206. doi:10.1002/sim.8528
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。